Analysts Expect Halozyme Therapeutics, Inc. (HALO) Will Post Earnings of $0.01 Per Share

Wall Street brokerages forecast that Halozyme Therapeutics, Inc. (NASDAQ:HALO) will announce $0.01 earnings per share for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Halozyme Therapeutics’ earnings. The highest EPS estimate is $0.10 and the lowest is ($0.11). Halozyme Therapeutics posted earnings per share of ($0.19) during the same quarter last year, which suggests a positive year over year growth rate of 105.3%. The company is expected to issue its next quarterly earnings report on Thursday, May 9th.

According to Zacks, analysts expect that Halozyme Therapeutics will report full-year earnings of ($0.43) per share for the current financial year, with EPS estimates ranging from ($0.51) to ($0.39). For the next year, analysts anticipate that the business will post earnings of ($0.40) per share, with EPS estimates ranging from ($0.87) to ($0.22). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow Halozyme Therapeutics.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Thursday, February 21st. The biopharmaceutical company reported ($0.01) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.03) by $0.02. Halozyme Therapeutics had a negative net margin of 52.90% and a negative return on equity of 31.86%. The business had revenue of $60.23 million during the quarter, compared to the consensus estimate of $59.77 million. During the same period in the previous year, the firm posted $0.85 earnings per share. The business’s revenue for the quarter was down 68.2% compared to the same quarter last year.

Several research firms have recently commented on HALO. Zacks Investment Research downgraded shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, January 11th. BidaskClub downgraded shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, March 6th. Finally, ValuEngine downgraded shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, March 6th. One analyst has rated the stock with a sell rating, four have given a hold rating and three have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $20.17.

NASDAQ:HALO opened at $16.10 on Friday. Halozyme Therapeutics has a 12 month low of $13.24 and a 12 month high of $20.54. The company has a debt-to-equity ratio of 0.14, a current ratio of 2.86 and a quick ratio of 2.71. The firm has a market cap of $2.34 billion, a PE ratio of -28.75 and a beta of 1.87.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its position in Halozyme Therapeutics by 4.9% during the third quarter. Vanguard Group Inc. now owns 13,317,364 shares of the biopharmaceutical company’s stock valued at $241,977,000 after purchasing an additional 622,518 shares during the period. Vanguard Group Inc lifted its position in Halozyme Therapeutics by 4.9% during the third quarter. Vanguard Group Inc now owns 13,317,364 shares of the biopharmaceutical company’s stock valued at $241,977,000 after purchasing an additional 622,518 shares during the period. BB Biotech AG lifted its position in Halozyme Therapeutics by 0.9% during the fourth quarter. BB Biotech AG now owns 8,322,860 shares of the biopharmaceutical company’s stock valued at $121,763,000 after purchasing an additional 75,000 shares during the period. JPMorgan Chase & Co. lifted its position in Halozyme Therapeutics by 12.5% during the third quarter. JPMorgan Chase & Co. now owns 3,601,604 shares of the biopharmaceutical company’s stock valued at $65,441,000 after purchasing an additional 400,008 shares during the period. Finally, Thrivent Financial for Lutherans lifted its position in Halozyme Therapeutics by 13.6% during the fourth quarter. Thrivent Financial for Lutherans now owns 3,562,505 shares of the biopharmaceutical company’s stock valued at $52,120,000 after purchasing an additional 426,775 shares during the period. Institutional investors own 83.38% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.

Read More: Dollar Cost Averaging

Get a free copy of the Zacks research report on Halozyme Therapeutics (HALO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.